Leerink Swann Upgrades Vivus (VVUS) to Outperform; Becoming A More Attractive Asset For Big Pharma After Qnexa Approval
Tweet Send to a FriendGet Alerts VVUS Hot Sheet
Price: $12.30 -1.91%
Rating Summary:
6 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
6 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade VVUS Now!
Leerink Swann upgraded Vivus (NASDAQ: VVUS) to Outperform.
Analyst, Joshua Schimmer, said, "Yesterday, the FDA advisory panel voted 20-2 for approval of Qnexa. Although some panel members expressed concerns about the need for a CV outcomes trial, it did not deter them from voting in favor of approval. We expect Qnexa to generate significant sales upon 3Q12 launch and VVUS could become an attractive asset for a company seeking to leverage its primary care salesforce. We upgrade to Outperform and raise our valuation to high $20's."
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $10.55 yesterday, with a 52 week range of $6.00-$13.18.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Joshua Schimmer, said, "Yesterday, the FDA advisory panel voted 20-2 for approval of Qnexa. Although some panel members expressed concerns about the need for a CV outcomes trial, it did not deter them from voting in favor of approval. We expect Qnexa to generate significant sales upon 3Q12 launch and VVUS could become an attractive asset for a company seeking to leverage its primary care salesforce. We upgrade to Outperform and raise our valuation to high $20's."
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $10.55 yesterday, with a 52 week range of $6.00-$13.18.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Leerink Swann Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform
- UPDATE: Vanda Pharmaceuticals (VNDA) Opens Higher; Lazard Raises PT to $17
- RBC Capital Upgrades U.S. Silica Holdings (SLCA) to Outperform
Create E-mail Alert Related Categories
Analyst EPS Change, Rumors, Upgrades
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
